The Investor Relations department of Evotec SE acts as an interface between the company and the capital markets. Our extensive investor relations work focuses on an active, regular, comprehensive and transparent dialogue with our stakeholders, including shareholders, existing and potential investors, analysts, banks and the financial press. The various interest groups are provided with all important information about the company and have the opportunity to form a comprehensive picture of the company as well as to assess its future development in the best possible way.
Our Equity Story
We are pioneering drug discovery and development by leveraging cutting-edge technology, disruptive science, and AI-driven innovation. In collaboration with our partners, we accelerate the journey from concept to cure.
By integrating molecular patient data, patient-derived disease modelling, and omics-driven drug discovery, we ensure the right therapies reach the right patients—sooner, safer, and smarter. We are revolutionizing medicine through data, intelligence, and relentless innovation.
Our value creation strategy is built on four core pillars:
- Achieving above-market growth rates and higher-quality earnings, driven by our technological leadership and innovation.
- A strong commitment to operational excellence across all areas of the business.
- Just – Evotec Biologics: a key growth engine, with an emphasis on further monetizing our existing technologies and assets.
- A robust pipeline of assets, supported by credible partners, with significant associated milestones and royalty opportunities.
Sustainability is a core business imperative. By reducing lab time (and therefore energy usage), minimizing waste, and optimizing the use of natural resources, we not only operate more responsibly but also support the sustainability ambitions of our partners.
The combination of our capabilities and unique business model is only beginning to deliver strong operational growth and long-term value creation for all stakeholders.
Our Growth Strategy
We aim to grow faster than the market by focusing on high-value, high-growth segments with strong margins—segments that demand differentiated solutions.
Shared R&D
We are building growth momentum through a tailored commercial model that strengthens our position in long-term strategic collaborations while maximizing our platform’s full potential for targeted projects.
- Industrialisation and automation enable consistent, high-quality results—whether for a single experiment or a multi-year collaboration.
- Our standardized offerings prioritize speed, ease of business, and industry-leading quality standards.
- Integrated projects include additional services to accelerate results, offering access to our expert teams and consulting support.
- The "gold standard" of our services becomes the foundation of strategic partnerships, providing clients with exclusive access to next-generation technologies and therapeutic area (TA) expertise.
- As complexity and proprietary technology access increase, the proportion of value-added revenue—such as milestones, licensing, and royalties—also rises in the event of a drug's commercial success.
Just – Evotec Biologics
We are continuously refining our business model to better leverage existing technologies and resources in a highly capital-efficient way.
- Our core focus remains on enabling technologies for end-to-end continuous manufacturing, where we lead the global field.
- In line with our Group strategy, we aim to further expand leadership in process technologies, cell lines, and beyond, while evolving our commercial model.
- We are confident in our ability to broaden our addressable market beyond the traditional CDMO (Contract Development and Manufacturing Organisation) space, with a vision to operate with a leaner CAPEX footprint.
